Loading...
Market
Which region will have the highest sales of Zenrelia™ by mid-2025?
2
Resolution / Starting Odds
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other regions • 25%
Elanco's sales reports and market research data
Story
FDA Approves Elanco's Zenrelia™ for Dogs, Shares Up 2%
Sep 19, 2024, 07:18 PM
The U.S. Food and Drug Administration (FDA) has approved Elanco Animal Health's new skin disease treatment for dogs, Zenrelia™ (ilunocitinib tablets). This approval marks a significant advancement in canine dermatology, offering an effective and safe solution for treating skin conditions in dogs. The announcement has positively impacted Elanco's market performance, with the company's shares rising by 2% in afternoon trade.
View original story
Similar markets
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other regions • 25%
Northeast • 25%
Midwest • 25%
South • 25%
West • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
Northeast • 25%
Midwest • 25%
South • 25%
West • 25%
Asia-Pacific • 25%
North America • 25%
Europe • 25%
Other • 25%
Africa • 25%
Asia • 25%
Latin America • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Africa • 25%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Other • 25%